EG24180A - Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer - Google Patents

Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Info

Publication number
EG24180A
EG24180A EG20010660A EG20010660A EG24180A EG 24180 A EG24180 A EG 24180A EG 20010660 A EG20010660 A EG 20010660A EG 20010660 A EG20010660 A EG 20010660A EG 24180 A EG24180 A EG 24180A
Authority
EG
Egypt
Prior art keywords
farnesyl transferase
transferase inhibiting
quinoline enantiomer
annelated quinoline
annelated
Prior art date
Application number
EG20010660A
Other languages
English (en)
Inventor
Marc G Venet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of EG24180A publication Critical patent/EG24180A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EG20010660A 2000-06-22 2001-06-20 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer EG24180A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22

Publications (1)

Publication Number Publication Date
EG24180A true EG24180A (en) 2008-09-28

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010660A EG24180A (en) 2000-06-22 2001-06-20 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Country Status (34)

Country Link
US (3) US20030114471A1 (ja)
EP (1) EP1296984B1 (ja)
JP (1) JP4919575B2 (ja)
KR (2) KR100846370B1 (ja)
CN (1) CN1207296C (ja)
AR (1) AR030704A1 (ja)
AT (1) ATE294804T1 (ja)
AU (3) AU2001263962B2 (ja)
BG (1) BG65894B1 (ja)
BR (1) BRPI0111743B8 (ja)
CA (1) CA2410232C (ja)
CZ (1) CZ295278B6 (ja)
DE (1) DE60110592T2 (ja)
EA (1) EA005065B1 (ja)
EE (1) EE04966B1 (ja)
EG (1) EG24180A (ja)
ES (1) ES2241830T3 (ja)
HK (1) HK1058363A1 (ja)
HR (1) HRP20020989B1 (ja)
HU (1) HU229095B1 (ja)
IL (2) IL153560A0 (ja)
IS (1) IS2596B (ja)
JO (1) JO2361B1 (ja)
MX (1) MXPA02012845A (ja)
MY (1) MY127734A (ja)
NO (1) NO324494B1 (ja)
NZ (1) NZ522481A (ja)
PA (1) PA8519501A1 (ja)
PL (1) PL209521B1 (ja)
SA (1) SA01220349B1 (ja)
SK (1) SK285699B6 (ja)
UA (1) UA73572C2 (ja)
WO (1) WO2001098302A1 (ja)
ZA (1) ZA200210305B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
SG10202101740QA (en) 2015-08-17 2021-04-29 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー, インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PL190944B1 (pl) * 1997-04-25 2006-02-28 Janssen Pharmaceutica Nv Pochodna chinazolinonu i sposób jej wytwarzania oraz kompozycja farmaceutyczna i sposób jej wytwarzania
RU2209066C2 (ru) 1997-06-02 2003-07-27 Янссен Фармацевтика Н.В. Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы
ES2199579T3 (es) * 1998-07-06 2004-02-16 Janssen Pharmaceutica N.V. Inhibidores de la proteina farnesil-transferasa con propiedades de sensibilizacion in vivo.
HU229358B1 (en) 1998-07-06 2013-11-28 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
NZ509372A (en) * 1998-08-27 2003-08-29 Pfizer Prod Inc Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer)
WO2000012498A1 (en) * 1998-08-27 2000-03-09 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
DE69907964T2 (de) * 1998-12-23 2004-02-19 Janssen Pharmaceutica N.V. 1,2-annelierte chinolinderivate
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
OA11833A (en) * 1999-02-11 2005-08-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
DE60130976T2 (de) * 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Also Published As

Publication number Publication date
UA73572C2 (en) 2005-08-15
HK1058363A1 (en) 2004-05-14
HU229095B1 (en) 2013-07-29
CZ295278B6 (cs) 2005-06-15
CZ2003114A3 (cs) 2003-05-14
HRP20020989A2 (en) 2005-02-28
EA200300048A1 (ru) 2003-04-24
CA2410232A1 (en) 2001-12-27
PA8519501A1 (es) 2002-08-29
MY127734A (en) 2006-12-29
AU2006220405A1 (en) 2006-10-12
ATE294804T1 (de) 2005-05-15
US8318753B2 (en) 2012-11-27
US20070259902A1 (en) 2007-11-08
ES2241830T3 (es) 2005-11-01
JP4919575B2 (ja) 2012-04-18
HUP0300872A3 (en) 2004-11-29
BG65894B1 (bg) 2010-04-30
AU2006220405B2 (en) 2009-05-21
BR0111743A (pt) 2003-07-08
CN1207296C (zh) 2005-06-22
KR20030009463A (ko) 2003-01-29
DE60110592T2 (de) 2006-01-19
US20080114009A1 (en) 2008-05-15
PL209521B1 (pl) 2011-09-30
EE04966B1 (et) 2008-02-15
EE200200695A (et) 2004-06-15
EA005065B1 (ru) 2004-10-28
NO20026032D0 (no) 2002-12-16
IS6590A (is) 2002-10-25
AR030704A1 (es) 2003-09-03
SK285699B6 (sk) 2007-06-07
SK502003A3 (en) 2003-05-02
HUP0300872A2 (hu) 2003-07-28
ZA200210305B (en) 2004-03-19
BG107310A (bg) 2003-07-31
WO2001098302A1 (en) 2001-12-27
PL358918A1 (en) 2004-08-23
IL153560A (en) 2011-06-30
IL153560A0 (en) 2003-07-06
EP1296984B1 (en) 2005-05-04
AU6396201A (en) 2002-01-02
EP1296984A1 (en) 2003-04-02
CN1437601A (zh) 2003-08-20
KR100831940B1 (ko) 2008-05-23
BRPI0111743B1 (pt) 2019-03-26
MXPA02012845A (es) 2003-05-15
HRP20020989B1 (en) 2011-05-31
NO324494B1 (no) 2007-10-29
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
CA2410232C (en) 2008-10-07
US8329714B2 (en) 2012-12-11
IS2596B (is) 2010-03-15
NZ522481A (en) 2004-09-24
JO2361B1 (en) 2006-12-12
US20030114471A1 (en) 2003-06-19
SA01220349B1 (ar) 2007-01-23
KR100846370B1 (ko) 2008-07-15
BRPI0111743B8 (pt) 2021-05-25
KR20070121847A (ko) 2007-12-27
AU2001263962B2 (en) 2006-07-20
NO20026032L (no) 2002-12-16

Similar Documents

Publication Publication Date Title
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
MY117961A (en) Inhibitors of farnesyl protein transferase
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
RS20060004A (en) Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
EG24180A (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
DE50211929D1 (en) Pyrimidinderivate
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
WO2001060458A3 (en) Inhibitors of prenyl-protein transferase
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MY122477A (en) Sertraline oral concentrate
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
TH59553B (th) 1,2-แอนเนเลเทด ควิโนลีน อิแนนซิโอเมอร์ ซึ่งมีฤทธิ์ยับยั้งฟาร์เนซิลทรานส์เฟอเรส